logo

Health News

Share SHARE
ecigs-091516-lg.jpg

The rise of e-cigarettes may be increasing the rates at which people are quitting smoking, according to a new study from researchers at the U.K. Center for Tobacco and Alcohol Studies at the University of Nottingham. For the study, the researchers examined the prevalence of smoking in the U.K. between 2014 and 2015 and found as e-cigarettes increased in popularity, more people reported quitting.
More
PregnantWoman-082616.jpgWomen who take acetaminophen during pregnancy are more likely to have a hyperactive child, according to a new study. The study, published in JAMA Pediatrics, found that more than half the mothers (4,415 women or 53 percent) reported using acetaminophen at 18 weeks of pregnancy, while fewer than half (3,381 women or 42 percent) reported using it at 32 weeks.
More
duster-091516.jpg As much as 45 toxic chemicals can be found in everyday common house dust, according to a new study. The new study, which saw researchers analyze all studies that have sampled indoor environments in the United States since 2000, found that the chemicals found in dust samples came from a range of things typically found inside your home, including vinyl products, such as flooring and cosmetics. peperwork-090816.jpg Doctors spend nearly half of their time attending to paperwork, according to a new study from researchers at the University of Washington Medicine. For the study the researchers polled 57 doctors in various practices about what consumes most of their time on a daily basis. "I think we need to make things better because patients notice that doctors are spending more time with the computer . . ." More

FDA Warns Some Ovarian Cancer Tests Could Be Ineffective



The FDA has issued up a warning that some forms of ovarian cancer tests may not be reliable. In a statement the agency has explained that several of the most reliable forms of screening are blood tests, but they may actually create spikes in the very biomarkers they are seeking. "Despite extensive research and published studies, there are currently no screening tests for ovarian cancer . . ."
More




Follow RTT
FDA Calendar
Event DateSymbolDrug NameEvent Name
12/15/16DVAXHEPLISAV-B (BLA)FDA decision on HEPLISAV-B for immunization of adults against hepatitis B infection
12/11/16SPPIEOquin, now Qapzola (NDA)FDA decision on Qapzola for the treatment of non-invasive bladder cancer
11/30/16LXRXTelotristat Etiprate (NDA)FDA decision on Telotristat Etiprate for the treatment of carcinoid syndrome
11/16/16VRX, VRX.TOBrodalumab (BLA)FDA decision on Brodalumab for treatment of patients with moderate-to-severe plaque psoriasis.
11/16/16DVAXHEPLISAV-B (BLA)FDA panel review of HEPLISAV-B for immunization of adults against hepatitis B infection
11/12/16GILDTenofovir Alafenamide (TAF) (NDA)FDA decision on TAF for treatment of chronic hepatitis B
More FDA Calendar Data

FDA Device Approval
No Records Found
More FDA Device Approval Data